new Risk Evaluation and Mitigation Strategy (REMS) to reduce the misuse of long-acting opioids

FDA will encourage you to participate in a new Risk Evaluation and Mitigation Strategy (REMS) to reduce the misuse of long-acting opioids.

Unintentional deaths due to opioids have quadrupled in 8 years...and treatment for opioid abuse has increased five-fold in 10 years.

Now FDA will require manufacturers to come up with a REMS plan by mid-August...with the changes rolled out by early 2012.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote